Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence

Link to article at PubMed

Int J Cardiol. 2020 Sep 28:S0167-5273(20)33894-8. doi: 10.1016/j.ijcard.2020.09.064. Online ahead of print.


In patients with severe or critical Coronavirus disease 2019 (COVID-19) manifestations, a thromboinflammatory syndrome, with diffuse microvascular thrombosis, is increasingly evident as the final step of pro-inflammatory cytokines storm. Actually, no proven effective therapies for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection exist. Preliminary observations on anticoagulant therapy appear to be associated with better outcomes in moderate and severe COVID-19 patients with signs of coagulopathy and in those requiring mechanical ventilation. The pathophysiology underlying the prothrombotic state elicited by SARS-CoV-2 outlines possible protective mechanisms of antithrombotic therapy (in primis anticoagulants) for this viral illness. The indications for antiplatelet/anticoagulant use (prevention, prophylaxis, therapy) are guided by the clinical context and the COVID-19 severity. We provide a practical approach on antithrombotic therapy management for COVID-19 patients from a multidisciplinary point of view.

PMID:33002521 | DOI:10.1016/j.ijcard.2020.09.064

Leave a Reply

Your email address will not be published. Required fields are marked *